Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link FDA to Convene Pharmacy Compounding Advisory Committee in July FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies